Long-term serological follow-up of blood donors with an HTLV-indeterminate western blot: antibody profile of seroconverters and individuals with false reactions.
The high proportion of indeterminate results of the screening test for human T-lymphotropic virus (HTLV) infection has been a challenge worldwide. In this study, 60 persons with seroindeterminate results for HTLV were followed until their serological status was defined. At least two independent serological tests (EIA and WB) from sequential samples were performed at an average interval of 4.4 years, totaling 141 serum samples tested. Seroconversion occurred in 12 individuals (reactive by EIA, positive by WB and PCR), and 48 were classified as false reactions (non-reactive EIA and negative PCR, but indeterminate WB). The seroconverter group had epidemiological features similar to those seen in HTLV-1 carriers, and the average time of follow-up for seroconversion was 4 years. In the group with false reactions, the most frequent indeterminate WB pattern in the samples was the presence of p24 alone. This pattern was absent in the seroconverter group, suggesting that p24 alone is an indicator of false reactivity. In contrast, the presence of p19 and p24 seems to be an indicator of true reactivity, since this pattern was frequent (66.7%) among the seroconverters and much less common (10.4% of the first samples) among the individuals with false reactions (P = 0.0001). Thus, HTLV infection may be suspected when reactivity to p19 and p24 is observed. Individuals with an indeterminate WB pattern should be followed-up and retested. The improvement of the HTLV algorithm screening of blood donors has been necessary to reduce inconclusive results and to avoid unnecessary follow-up to define the status of infection.
Martins
Marina Lobato
ML
Minas Gerais State Blood Center, Fundação Hemominas, Minas Gerais, Brazil.
Santos
Ana Carolina da Silva
AC
Namen-Lopes
Maria Sueli
MS
Barbosa-Stancioli
Edel Figueiredo
EF
Utsch
Denise Gonçalves
DG
Carneiro-Proietti
Anna Bárbara de F
AB
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D001782:Blood Donors; D015153:Blotting, Western / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D015490:HTLV-I Infections / Q000175:diagnosis*; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods; D008297:Male; D008875:Middle Aged; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology; D014773:Virology / Q000379:methods; D055815:Young Adult; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000276:immunology
D000914:Antibodies, Viral; D015682:Retroviridae Proteins, Oncogenic; D054301:gag Gene Products, Human Immunodeficiency Virus; C060955:p19 protein, Human T-lymphotropic virus 1; C060954:p24 protein, Human T-lymphotropic virus 1